• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

链球菌纤维蛋白溶解系统(链激酶)对兔血管内血栓的溶解作用。

The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase).

作者信息

JOHNSON A J, TILLETT W S

出版信息

J Exp Med. 1952 May 1;95(5):449-64. doi: 10.1084/jem.95.5.449.

DOI:10.1084/jem.95.5.449
PMID:14927798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2212084/
Abstract
  1. Based upon quantitative estimations of the factors that promote or retard the development and activity of the streptococcal fibrinolytic phenomenon, an active lytic system was developed within the circulating blood stream of rabbits following the intravenous infusion of streptokinase. During the infusion of adequate doses of SK, an active lytic system was observed to be present within 30 minutes following the beginning of the experiment and remained present for periods of time ranging from 1 to 20 hours depending primarily upon the concentration of SK and the duration of the infusion. Some of the biochemical changes accompanying the lytic system in vivo were: (a) a striking fall in the plasminogen; (b) a moderate fall in the serum inhibitor and the fibrinogen; and, (c) a rise in the acid-soluble nitrogen. These changes were usually self-terminating within 24 hours following the infusion of SK. In earlier studies similar trends were observed in the chest fluid of patients with hemothorax and empyema treated locally with streptokinase (22). 2. Intravascular clots, induced artificially by local applications of sodium morrhuate within the ear vein of the rabbits, were observed to liquefy and disappear in 23 of 25 rabbits during the intravenous infusion of SK into the opposite ear. The average quantity of SK necessary to effect an active lytic system was found to be about 40,000 units per kilo per hour. The clot in the ear vein was observed to be lysed completely in periods of time ranging from 3 to 7 hours after the infusion of SK was begun. Maintenance of an active lytic system for 3 to 4 additional hours was required to prevent re-formation of the clots at the original site. In 3 of 4 rabbits in which clots did reform, ACTH had been given to combat the toxic effects of the streptococcal concentrates. 3. The toxicity of the unusually large dose of the streptococcal concentrates, containing measured amounts of SK, along with other identifiable and unknown substances, was considerable, inasmuch as 8 animals eventually died. No evidence of pulmonary infarction was observed at autopsy. The administration of ACTH appeared to prevent a fatal outcome in at least 3 of the rabbits. Further studies of toxicity are in progress.
摘要
  1. 根据对促进或抑制链球菌纤溶现象发展及活性的因素进行的定量评估,在静脉输注链激酶后,兔的循环血流中形成了一个活性溶解系统。在输注足够剂量的链激酶期间,实验开始后30分钟内观察到活性溶解系统存在,并且主要取决于链激酶的浓度和输注持续时间,该系统会持续存在1至20小时不等。体内伴随溶解系统出现的一些生化变化包括:(a)纤溶酶原显著下降;(b)血清抑制剂和纤维蛋白原适度下降;以及(c)酸溶性氮增加。这些变化通常在输注链激酶后24小时内自行终止。在早期研究中,在局部用链激酶治疗的血胸和气胸患者的胸液中也观察到了类似趋势(22)。2. 在兔耳静脉局部应用鱼肝油酸钠人工诱导血管内血栓形成,在向对侧耳静脉输注链激酶期间,观察到25只兔中有23只的血栓液化并消失。发现产生活性溶解系统所需的链激酶平均量约为每千克每小时40,000单位。在开始输注链激酶后3至7小时内观察到耳静脉中的血栓完全溶解。需要再维持活性溶解系统3至4小时以防止血栓在原部位重新形成。在4只血栓确实重新形成的兔中,有3只给予了促肾上腺皮质激素以对抗链球菌浓缩物的毒性作用。3. 含有一定量链激酶以及其他可识别和未知物质的超大剂量链球菌浓缩物毒性相当大,因为最终有8只动物死亡。尸检未观察到肺梗死的证据。促肾上腺皮质激素的给药似乎至少使3只兔避免了致命结局。关于毒性的进一步研究正在进行中。

相似文献

1
The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase).链球菌纤维蛋白溶解系统(链激酶)对兔血管内血栓的溶解作用。
J Exp Med. 1952 May 1;95(5):449-64. doi: 10.1084/jem.95.5.449.
2
The influence of various combinations of plasminogen and streptokinase on fibrinolysis.纤溶酶原与链激酶的不同组合对纤维蛋白溶解的影响。
Haemostasis. 1981;10(6):304-14. doi: 10.1159/000214416.
3
Intermittent plasminogen-streptokinase treatment of deep vein thrombosis.间歇性纤溶酶原-链激酶治疗深部静脉血栓形成
Haemostasis. 1988;18 Suppl 1:127-38. doi: 10.1159/000215848.
4
Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism.酰基酶作为静脉血栓形成和肺栓塞犬模型中的溶栓剂。
Thromb Haemost. 1984 Apr 30;51(2):248-53.
5
[Local thrombolysis in peripheral arterial occlusion].[外周动脉闭塞的局部溶栓治疗]
Herz. 1989 Feb;14(1):12-21.
6
High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation.急性心肌梗死中链激酶大剂量、短疗程静脉输注:对循环系统影响的描述
Am J Cardiol. 1986 Jun 1;57(15):1220-6. doi: 10.1016/0002-9149(86)90192-x.
7
The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.在一种新的兔静脉血栓形成模型中对纤溶酶和链激酶激活剂复合物的评估。
Thromb Haemost. 1981 Aug 28;46(2):528-34.
8
LYS-plasminogen shortens the duration of local thrombolytic treatment of peripheral arterial occlusions--a randomized controlled trial.赖氨酸纤溶酶原缩短外周动脉闭塞局部溶栓治疗的持续时间——一项随机对照试验。
Wien Klin Wochenschr. 1999 Jan 15;111(1):21-5.
9
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.葡萄球菌激酶与链激酶在静脉血栓形成动物模型中的纤溶特性比较
Thromb Haemost. 1991 Oct 1;66(4):468-73.
10
Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.用尿激酶和链激酶治疗深静脉血栓形成期间的全身纤维蛋白溶解活性和抑制剂水平。
Thromb Haemost. 1983 Oct 31;50(3):664-8.

引用本文的文献

1
Bleeding Complications of Anticoagulation Therapy Used in the Treatment of Acute Coronary Syndromes-Review of the Literature.用于治疗急性冠脉综合征的抗凝治疗的出血并发症——文献综述
J Clin Med. 2025 May 13;14(10):3391. doi: 10.3390/jcm14103391.
2
Treatment of Pulmonary Embolism beyond Anticoagulation.除抗凝治疗外的肺栓塞治疗
Curr Pharm Des. 2024;30(18):1382-1385. doi: 10.2174/0113816128308493240418075258.
3
Thrombolytic Enzymes of Microbial Origin: A Review.微生物来源的溶栓酶:综述。
Int J Mol Sci. 2021 Sep 28;22(19):10468. doi: 10.3390/ijms221910468.
4
Fibrinolytic Enzymes for Thrombolytic Therapy.纤维蛋白溶解酶用于溶栓治疗。
Adv Exp Med Biol. 2019;1148:345-381. doi: 10.1007/978-981-13-7709-9_15.
5
Intravenous thrombolytics for ischemic stroke.静脉溶栓治疗缺血性脑卒中。
Neurotherapeutics. 2011 Jul;8(3):388-99. doi: 10.1007/s13311-011-0049-x.
6
A history of streptokinase use in acute myocardial infarction.急性心肌梗死中使用链激酶的病史。
Tex Heart Inst J. 2007;34(3):318-27.
7
Total Hyphema with Special Reference to Treatment of the Experimental Lesion.全前房积血及其对实验性损伤治疗的特别参考
Trans Am Ophthalmol Soc. 1963;61:638-81.
8
[Fetal fibrinogen. II. Studies on the fibrinolytic resistance of "umbilical vein fibrin"].[胎儿纤维蛋白原。II. “脐静脉纤维蛋白”纤溶抗性的研究]
Klin Wochenschr. 1962 May 1;40:478-81. doi: 10.1007/BF01737060.
9
The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase.通过静脉输注链激酶对人体人工诱导的血管内血栓进行溶解。
J Clin Invest. 1959 Sep;38(9):1627-43. doi: 10.1172/JCI103941.
10
Behavior in the circulation of the radioactive pulmonary embolus and its application to the study of fibrinolytic enzymes.放射性肺栓塞在循环中的行为及其在纤溶酶研究中的应用。
Ann Surg. 1960 Apr;151(4):507-16. doi: 10.1097/00000658-196004000-00010.

本文引用的文献

1
Effects of intravenous injection in dogs of staphylokinase and dog serum fibrinolysin.葡萄球菌激酶和犬血清纤维蛋白溶酶静脉注射对犬的影响。
Proc Soc Exp Biol Med. 1949 Aug;71(4):677-80. doi: 10.3181/00379727-71-17297.
2
QUANTITATIVE MICRO-ESTIMATION OF ANTIBODIES IN THE SERA OF MAN AND OTHER ANIMALS.定量微量估计人与其他动物血清中的抗体。
Science. 1943 Apr 30;97(2522):405-6. doi: 10.1126/science.97.2522.405.
3
THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS.链球菌纤维蛋白溶酶(链激酶)和链球菌脱氧核糖核酸酶对患者纤维蛋白性、脓性和血性胸腔渗出液的作用
J Clin Invest. 1949 Jan;28(1):173-90. doi: 10.1172/JCI102046.
4
A STUDY OF ANTIFIBRINOLYSIN ACTIVITY IN THE PLASMAS OF VARIOUS ANIMAL SPECIES.不同动物物种血浆中抗纤维蛋白溶酶活性的研究。
J Clin Invest. 1948 Nov;27(6):785-92. doi: 10.1172/JCI102029.
5
Hypercoagulability of the blood associated with ACTH and cortisone therapy.与促肾上腺皮质激素和可的松治疗相关的血液高凝状态。
Am J Med. 1950 Dec;9(6):752-6. doi: 10.1016/0002-9343(50)90290-7.
6
The use of streptokinase-streptodornase in the treatment of hemothorax.链激酶-链道酶在血胸治疗中的应用。
J Thorac Surg. 1950 Sep;20(3):393-417.